Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Akcea Therapeutics, Inc. (AKCA) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Akcea Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1662524.
Total stock buying since 2017: $610,464,514.
Total stock sales since 2017: $3,581,373.
Total stock option exercises since 2017: $21,483,947.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2020 | 21,237,715 | $385,464,527 | 23,740 | $341,239 | 0 | $0 |
| 2019 | 0 | $0 | 101,992 | $3,240,134 | 2,583,466 | $21,483,947 |
| 2018 | 10,666,666 | $199,999,987 | 0 | $0 | 0 | $0 |
| 2017 | 3,125,000 | $25,000,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2020-10 | 21,237,715 | $385,464,527 | 0 | $0 | 0 | $0 |
| 2020-09 | 0 | $0 | 9,748 | $176,633 | 0 | $0 |
| 2020-07 | 0 | $0 | 263 | $3,287 | 0 | $0 |
| 2020-03 | 0 | $0 | 13,729 | $161,319 | 0 | $0 |
| 2019-09 | 0 | $0 | 0 | $0 | 2,483,293 | $20,834,827 |
| 2019-07 | 0 | $0 | 1,819 | $42,782 | 0 | $0 |
| 2019-04 | 0 | $0 | 81,787 | $2,606,500 | 81,787 | $529,979 |
| 2019-03 | 0 | $0 | 18,386 | $590,852 | 18,386 | $119,141 |
| 2018-04 | 10,666,666 | $199,999,987 | 0 | $0 | 0 | $0 |
| 2017-07 | 3,125,000 | $25,000,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-10-10 | Ionis Pharmaceuticals Inc (10% Owner) | Buy | 21,237,715 | 18.15 | 385,464,527 |
| 2020-09-22 | Patterson Joshua F. (General Counsel) | Sale | 319 | 18.12 | 5,780 |
| 2020-09-22 | Jenne Kyle (Chief Commercial Officer) | Sale | 720 | 18.12 | 13,046 |
| 2020-09-22 | Mcdevitt Damien (Chief Executive Officer) | Sale | 8,709 | 18.12 | 157,807 |
| 2020-07-17 | Patterson Joshua F. (General Counsel) | Sale | 263 | 12.50 | 3,287 |
| 2020-03-23 | Patterson Joshua F. (General Counsel) | Sale | 335 | 11.76 | 3,938 |
| 2020-03-23 | Jenne Kyle (Chief Commercial Officer) | Sale | 779 | 11.75 | 9,153 |
| 2020-03-23 | Mcdevitt Damien (Chief Executive Officer) | Sale | 9,417 | 11.75 | 110,649 |
| 2020-03-23 | O'dea Louis (Chief Medical Officer) | Sale | 3,198 | 11.75 | 37,579 |
| 2019-09-26 | Goldberg Jeff Marc (Chief Operating Officer) | Option Ex | 421,432 | 8.39 | 3,535,814 |
| 2019-09-26 | Soteropoulos Paula (Chief Executive Officer) | Option Ex | 2,061,861 | 8.39 | 17,299,013 |
| 2019-07-15 | Boyce Sarah (President) | Sale | 1,819 | 23.52 | 42,782 |
| 2019-04-08 | Goldberg Jeff Marc (Chief Operating Officer) | Sale | 20,000 | 31.72 | 634,420 |
| 2019-04-08 | Goldberg Jeff Marc (Chief Operating Officer) | Option Ex | 20,000 | 6.48 | 129,600 |
| 2019-04-08 | Soteropoulos Paula (Chief Executive Officer) | Sale | 1,787 | 32.17 | 57,480 |
| 2019-04-08 | Soteropoulos Paula (Chief Executive Officer) | Option Ex | 1,787 | 6.48 | 11,579 |
| 2019-04-05 | Goldberg Jeff Marc (Chief Operating Officer) | Sale | 30,000 | 31.71 | 951,300 |
| 2019-04-05 | Goldberg Jeff Marc (Chief Operating Officer) | Option Ex | 30,000 | 6.48 | 194,400 |
| 2019-04-05 | Soteropoulos Paula (Chief Executive Officer) | Sale | 30,000 | 32.11 | 963,300 |
| 2019-04-05 | Soteropoulos Paula (Chief Executive Officer) | Option Ex | 30,000 | 6.48 | 194,400 |
| 2019-03-06 | Soteropoulos Paula (Chief Executive Officer) | Sale | 18,386 | 32.14 | 590,852 |
| 2019-03-06 | Soteropoulos Paula (Chief Executive Officer) | Option Ex | 18,386 | 6.48 | 119,141 |
| 2018-04-17 | Ionis Pharmaceuticals Inc (10% Owner) | Buy | 10,666,666 | 18.75 | 199,999,987 |
| 2017-07-19 | Ionis Pharmaceuticals Inc (10% Owner) | Buy | 3,125,000 | 8.00 | 25,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of AKCA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Akcea Therapeutics, Inc. (symbol AKCA, CIK number 1662524) see the Securities and Exchange Commission (SEC) website.